[Controlled clinical trial of parsalmide in patients with predominantly neuro-anxiety syndromes. Comparison with chlordiazepoxide].
The anxiolytic and tranquillizing effect of a new compound called parsalmide was studied in a group of 20 patients suffering from medium anxiety neurosis. The new drug also possesses anti-inflammatory and analgesic effects. The technique employed was the double blind, between patients, crossover system and chlordiazepoxide was used for comparison purposes. Parsalmide proved to possess an anxiolytic-tranquillizing action comparable to that of chlordiazepoxide and, unlike the latter, was quite free from unpleasant side effects, such as somnolence and asthenia.
D000328:Adult; D000368:Aged; D014151:Anti-Anxiety Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000188:drug therapy*; D001549:Benzamides / Q000009:adverse effects / Q000627:therapeutic use*; D002707:Chlordiazepoxide / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged
D014151:Anti-Anxiety Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D001549:Benzamides; D002707:Chlordiazepoxide
Sperimentazione clinica controllata di parsalmide in pazienti con sindromi prevalentemente neuro-ansiose. Confronto con il clordiazepossido